Long-acting Beta Agonist Step Down Study

PHASE4CompletedINTERVENTIONAL
Enrollment

459

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

September 30, 2015

Study Completion Date

October 31, 2015

Conditions
Asthma
Interventions
DRUG

Fluticasone/Salmeterol Diskus

Continuation of Fluticasone/Salmeterol Diskus 250/50 ug twice daily

DRUG

Fluticasone/Salmeterol Diskus

Reduced dose Fluticasone/Salmeterol Diskus 100/50 ug twice daily

DRUG

Fluticasone Diskus

Fluticasone Diskus alone 250 ug twice daily without Salmeterol

Trial Locations (19)

10016

New York University School of Medicine, New York

10595

Maria Fareri Children's Hospital at Westchester Medical Center and New York Medical College, Valhalla

11040

Hofstra North Shore-LIJ School of Medicine, New Hyde Park

22908

University of Virginia, Charlottesville

27710

Duke University Medical Center, Durham

32207

Nemours Children's Clinic, Jacksonville

33613

University of Miami/University of South Florida, Tampa

43221

The Ohio State University Medical Center, Columbus

46260

St. Vincent Healthcare, Indianapolis

46290

St. Vincent Hospital and Health Care Center, Inc, Indianapolis

60611

The Illinois Consortium, Chicago

63110

Washington University/St. Louis University, St Louis

64108

University of Missouri, Kansas City School of Medicine, Kansas City

70112

Louisiana State University Health Sciences Center, The Ernest N. Morial Asthma, Allergy and Respiratory Disease Center, New Orleans

77030

Baylor College of Medicine, Houston

80206

National Jewish Health, Denver

85724

University of Arizona, Arizona Respiratory Center, Tucson

92103

University of California, San Diego, San Diego

05446

Northern New England Consortium, Colchester

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

American Lung Association

OTHER

collaborator

GlaxoSmithKline

INDUSTRY

lead

Johns Hopkins University

OTHER

NCT01437995 - Long-acting Beta Agonist Step Down Study | Biotech Hunter | Biotech Hunter